GlaxoSmithKline a global healthcare company that develops, manufactures and markets pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. I have a holding in my income portfolio (epic code: GSK).
Following on from the positive CHMP opinion on 22 November 2013, ViiV Healthcare yesterday announced that the European Commission has approved Tivicay (dolutegravir), an integrase inhibitor, for use in combination with other anti-retroviral medicinal products for the treatment of HIV infected adults and adolescents above 12 years of age.
Glaxo own 76.5% of the JV ViiV, with Pfizer at 13.5% and Shionogi
at 10%.
No comments:
Post a Comment